The estimated Net Worth of Vinayak Doraiswamy is at least $1.39 millió dollars as of 15 September 2022. Vinayak Doraiswamy owns over 4,983 units of Atricure Inc stock worth over $522,021 and over the last 3 years Vinayak sold ATRC stock worth over $866,865.
Vinayak has made over 2 trades of the Atricure Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Vinayak sold 4,983 units of ATRC stock worth $229,168 on 15 September 2022.
The largest trade Vinayak's ever made was selling 7,672 units of Atricure Inc stock on 12 July 2021 worth over $637,697. On average, Vinayak trades about 1,266 units every 43 days since 2021. As of 15 September 2022 Vinayak still owns at least 19,406 units of Atricure Inc stock.
You can see the complete history of Vinayak Doraiswamy stock trades at the bottom of the page.
Vinayak's mailing address filed with the SEC is 7555, Innovation Way, Innovation Business Center, Mason, Warren County, Ohio, 45040, United States.
Over the last 19 years, insiders at Atricure Inc have traded over $52,789,242 worth of Atricure Inc stock and bought 666,621 units worth $5,937,195 . The most active insiders traders include Scott William Drake, Group I, Llc Donoghue Danie... és Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of $548,410. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth $84,245.
atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.
Atricure Inc executives and other stock owners filed with the SEC include: